Exenatide: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Fix Cargo VARCHAR(300) overflow: blank structure, shorten mechanism, move chemistry/mechanism prose to PK/PD |
MDElliottMD (talk | contribs) Migrate <indication> tags to <problem> (Phase 2 of indications-to-problems rebuild) |
||
| Line 37: | Line 37: | ||
* Cardiovascular outcomes: '''non-inferior''' but not superior to placebo in T2DM (EXSCEL) — the only major GLP-1 RA CVOT not to demonstrate superiority<ref name="exscel">Holman RR, Bethel MA, Mentz RJ et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). ''NEJM'' 377(13):1228–39. doi:10.1056/NEJMoa1612917</ref> | * Cardiovascular outcomes: '''non-inferior''' but not superior to placebo in T2DM (EXSCEL) — the only major GLP-1 RA CVOT not to demonstrate superiority<ref name="exscel">Holman RR, Bethel MA, Mentz RJ et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). ''NEJM'' 377(13):1228–39. doi:10.1056/NEJMoa1612917</ref> | ||
| indications = < | | indications = <problem ref="diabetes-type-2" author="MDElliottMD"/> | ||
| dosing = <titration slug="byetta-standard" author="MDElliottMD" title="Byetta — standard T2DM titration"> | | dosing = <titration slug="byetta-standard" author="MDElliottMD" title="Byetta — standard T2DM titration"> | ||